PR NewsWire: Janssen Pharmaceuticals, Inc. today announced it has collaborated with Premier Inc. on the first and largest study of its kind to address an unmet medical need for hospitalized patients with atrial fibrillation (AF) who are at risk for ischemic (more…)
Premier Statement on E&C Hearing and Lower Drug Costs through Competition Act
Last Updated: March 2, 2017By Blair Childs, Senior Vice President of Public Affairs, Premier Inc. Members of the Premier healthcare alliance commend House Energy and Commerce Committee Chairman Greg Walden (R-OH), Ranking Member Frank Pallone (D-NJ) and members of the Health Subcommittee for its (more…)
Dr. Mimi Huizinga to Lead Premier Inc.’s Life Sciences Strategy
Last Updated: February 16, 2017CHARLOTTE, N.C. (February 14, 2017) — Premier Inc., a leading healthcare improvement company, has tapped its Chief Health Information Officer, Mimi Huizinga, MD, to drive its life sciences strategy forward. A physician executive with more than ten years of quality (more…)
GPOs Want Trump to Cut Red Tape and Speed Up the FDA to Boost Supplier Competition
Last Updated: February 6, 2017Modern Healthcare: Ebert, Hatcher and Premier COO Mike Alkire all said importation is only a short-term solution that ultimately could create shortages and disrupt access to medicines. Alkire said the drug industry needs more competitors in any given category in order (more…)
A Look Forward To Health Care In 2017: Top Five Trends
Last Updated: February 3, 2017Health Affairs Blog: Susan DeVore: The new year is already underway and we expect both a new Republican-dominated Congress and President Donald Trump to bring ambitious policy changes to health care. With significant pent up energy among the Republicans and a (more…)
Premier Inc. Statement on Biosimilar Legal Challenge
Last Updated: December 12, 2016By Michael J. Alkire, COO of Premier Members of the Premier alliance commend the solicitor general for recommending the Supreme Court hear the case of Sandoz v. Amgen. This landmark case could overturn a lower court decision requiring biosimilar manufacturers (more…)
How Payers are Tackling Value-Based Drug Pricing
Last Updated: October 28, 2016HealthcareDive: Over the past couple of years, Dr. Bimal Shah has seen dozens of value-based drug pricing contract negotiations falter. As vice president for the research division of Premier, a provider-owned healthcare improvement company, he oversees research to identify opportunities for (more…)
Premier Inc. Statement on AHA/FAH Drug Pricing Report
Last Updated: November 9, 2016By Blair Childs, Premier Senior Vice President of Public Affairs The study released by the American Hospital Association (AHA) and the Federation of American Hospitals (FAH) is consistent with the facts Premier has been sharing with the public over the (more…)
Real-World Evidence: From Volume to Value
Last Updated: October 21, 2016PharmExec: Bimal Shah: Real-world evidence (RWE) is the intersection between the structured rigor of the randomized clinical trial (RCT), and the clinical exposure a treatment receives once it enters medical practice. As explored in the following Roundtable discussion, drug manufacturers, (more…)
ExpiredHighlights of Management of Heart Failure with Reduced Ejection Fraction – Morning Session
Last Updated: August 2, 2016- August 23, 2016
11:00 am - 12:00 pm
Heart failure is a complex, progressive disease that carries a significant risk of hospitalization and death. In addition, heart failure has a substantial and increasing impact on patients and the healthcare system. Join this live webinar at 11 a.m. EDT on Tuesday, August 23, for an introduction to Entresto, a novel new agent used to (more…)